Skip to main content

Table 2 Treatment related adverse events

From: Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG)

  All grades Grades III-IV
  N % N %
Leukopenia 12 25.1 - -
Neutropenia 11 23.0 3 6.3
Anemia 38 79.1 - -
Thrombocytopenia 18 37.5 - -
Nausea 11 23.0 2 4.2
Vomiting 9 18.8 2 4.2
Diarrhea 13 27.2 3 6.3
Mucositis 3 6.3 - -
Dysgefsia 1 2.1   
Constipation 9 18.8 1 2.1
Abdominal pain 4 8.3   
Non cardiac chest pain 1 2.1   
Neurotoxicity 18 37.5 1 2.1
Seizures 1 2.1   
Headache 3 6.3   
Allergic reaction 1 2.1 1 -
Asthenia 264 54.2 2 4.2
Anorexia 5 10.4   
Cutaneous toxicity 1 2.1 - -
Fever 2 4.2 - -
Hemorrhage 1 2.1 - -
Hypertension 3 6.3 1 2.1
.1
Hand foot syndrome 1 2.1